ESC 365 - Early initiation of PCSK9 inhibitors in acute STEMI: Interim results of safety and efficacy from the EARLY-STEMI trial

ESC2025 Premium Access

Early initiation of PCSK9 inhibitors in acute STEMI: Interim results of safety and efficacy from the EARLY-STEMI trial

Session: Pharmacotherapy in acute coronary syndromes (1)

Topic: Pharmacotherapy

Speaker: Doctor M. Ali (Doha, QA)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Mohammed Thamer Ali

HMC Heart Hospital, Doha (Qatar)

0 follower

5 more presentations in this session

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

Speaker: Doctor M. Susanti (Jawa Timur, ID)

Impact of Beta-Blocker Prescription at Discharge on Long-term Clinical Outcomes in ST elevation Myocardial Infarction Patients with Reduced LVEF treated with Drug-eluting Stents

Speaker: Professor S. Park (Seoul, KR)

Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention and using direct oral anticoagulants

Speaker: Mr O. Emilsson (Lund, SE)

Impact of guidelines on Newer P2Y12 inhibitor use among ACS patients undergoing PCI

Speaker: Doctor M. Mohamed (London, GB)

Efficacy and safety of ticagrelor versus clopidogrel in acute myocardial infarction-associated cardiogenic shock: a propensity score-matched analysis

Speaker: Doctor M. Presume (Lisbon, PT)

Access the full session

Pharmacotherapy in acute coronary syndromes (1)

Speakers: Doctor M. Ali, Doctor M. Susanti, Professor S. Park, Mr O. Emilsson, Doctor M. Mohamed...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources